[11C]Erlotinib pharmacokinetics: an in vivo study using positron emission tomography in non-small cell lung cancer patients with and without erlotinib therapy.
Completed
- Conditions
- 10038666lung cancernon-small cell lung carcinoma
- Registration Number
- NL-OMON36826
- Lead Sponsor
- Vrije Universiteit Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 10
Inclusion Criteria
Patients with NSCLC, planned to receive erlotinib for therapy will be included in this study.
Patients age: between 18 and 70 years
Life expectancy of at least 12 weeks
Malignant lesion of at least 1.5 cm diameter within the chest as measured by CT
Performance status Karnofsky index >60%
Written informed consent
Exclusion Criteria
Claustrophobia
Pregnant or lactating patients
Metal implants in the thorax (e.g. pacemakers), interfering with PET/CT imaging
Concurrent treatment with experimental drugs
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>1) [11C]erlotinib pharmacokinetics with and without erlotinib therapy,</p><br>
- Secondary Outcome Measures
Name Time Method <p>2) comparison of venous versus arterial sampling for correcting pharmacokinetic<br /><br>input curves,<br /><br>3) relationship between [11C]erlotinib pharmacokinetics in tumor tissue and<br /><br>tumor blood flow with and without erlotinib therapy,<br /><br>4) assessing the correlation between uptake parameters from dynamic PET scans<br /><br>and static whole body scans, obtained by reconstructing the available dynamic<br /><br>PET data.<br /><br>5) Validate IDIF against continuous arterial sampling.</p><br>